These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 20806180)

  • 1. The safety and efficacy of biphasic insulin aspart 30 (BIAsp 30) in Iranians with type 2 diabetes: an open-label, non-randomised, multi-centre observational study--the Iran subgroup of the IMPROVE™ study.
    Esteghamati A; Rajabian R; Amini M; Bahrami A; Khamseh ME; Afkhami-Ardekani M; Rizi EP
    Endokrynol Pol; 2010; 61(4):364-70. PubMed ID: 20806180
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improved glycaemic control with BIAsp 30 in insulin-naïve type 2 diabetes patients inadequately controlled on oral antidiabetics: subgroup analysis from the IMPROVE study.
    Wenying Y; Benroubi M; Borzi V; Gumprecht J; Kawamori R; Shaban J; Shah S; Shestakova M; Ligthelm R; Valensi P;
    Curr Med Res Opin; 2009 Nov; 25(11):2643-54. PubMed ID: 19751116
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized, multinational, open-label, 2-period, crossover comparison of biphasic insulin aspart 30 and biphasic insulin lispro 25 and pen devices in adult patients with type 2 diabetes mellitus.
    Niskanen L; Jensen LE; Råstam J; Nygaard-Pedersen L; Erichsen K; Vora JP
    Clin Ther; 2004 Apr; 26(4):531-40. PubMed ID: 15189750
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biphasic insulin aspart 30: literature review of adverse events associated with treatment.
    Davidson J; Vexiau P; Cucinotta D; Vaz J; Kawamori R
    Clin Ther; 2005; 27 Suppl B():S75-88. PubMed ID: 16519039
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biphasic insulin aspart in type 2 diabetes mellitus: an evidence-based medicine review.
    Gough SC; Tibaldi J
    Clin Drug Investig; 2007; 27(5):299-324. PubMed ID: 17451279
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Starting or switching to biphasic insulin aspart 30 (BIAsp 30) in type 2 diabetes: a multicenter, observational, primary care study conducted in Finland.
    Mäkelä JK; Schmüser C; Askonen K; Saukkonen T
    Diabetes Res Clin Pract; 2012 Jan; 95(1):10-8. PubMed ID: 22078072
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of biphasic insulin aspart 30 in type 2 diabetes patients switched from either biphasic or basal human insulin: results from the Gulf cohort of the A1 chieve study.
    Almansari A; Khader S; Kharawagh A; AbdelFattah W; Badawy T
    Int J Clin Pract; 2014 Jul; 68(7):850-6. PubMed ID: 24548757
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and effectiveness of biphasic insulin aspart 30/70 (NovoMix 30) when switching from human premix insulin in patients with type 2 diabetes: subgroup analysis from the 6-month IMPROVE observational study.
    Shah S; Benroubi M; Borzi V; Gumprecht J; Kawamori R; Shaban J; Shestakova M; Wenying Y; Valensi P;
    Int J Clin Pract; 2009 Apr; 63(4):574-82. PubMed ID: 19210701
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and effectiveness of biphasic insulin aspart 30 (Biasp 30) in people with type 2 diabetes mellitus in the pakistani population: results from the A1chieve study.
    Hassan MI; Aamir AH; Miyan Z; Siddiqui LA; Qureshi MS; Shaikh MZ
    J Pak Med Assoc; 2012 Sep; 62(9):929-36. PubMed ID: 23139978
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The IMPROVE study--a multinational, observational study in type 2 diabetes: data from the Polish cohort.
    Gumprecht J; Zurawska G; Wolnik B; Dzida G
    Endokrynol Pol; 2008; 59(6):460-6. PubMed ID: 19347809
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intensification to biphasic insulin aspart 30/70 (BIAsp 30, NovoMix 30) can improve glycaemic control in patients treated with basal insulins: a subgroup analysis of the IMPROVE observational study.
    Gumprecht J; Benroubi M; Borzi V; Kawamori R; Shaban J; Shah S; Shestakova M; Wenying Y; Ligthelm R; Valensi P;
    Int J Clin Pract; 2009 Jun; 63(6):966-72. PubMed ID: 19504715
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insulin aspart: a review of its use in the management of type 1 and 2 diabetes mellitus.
    Chapman TM; Noble S; Goa KL
    Drugs; 2002; 62(13):1945-81. PubMed ID: 12215068
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Premixed insulin aspart 30 vs. premixed human insulin 30/70 twice daily: a randomized trial in Type 1 and Type 2 diabetic patients.
    Boehm BO; Home PD; Behrend C; Kamp NM; Lindholm A
    Diabet Med; 2002 May; 19(5):393-9. PubMed ID: 12027927
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of switching to biphasic insulin aspart 30 from human insulin in patients with poorly controlled type 2 diabetes in South Korea.
    Lee KH; Seo SJ; Smith-Palmer J; Palmer JL; White J; Valentine WJ
    Value Health; 2009; 12 Suppl 3():S55-61. PubMed ID: 20586983
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biphasic insulin aspart 30 treatment improves glycaemic control in patients with type 2 diabetes in a clinical practice setting: Chinese PRESENT study.
    Gao Y; Guo XH; Vaz JA;
    Diabetes Obes Metab; 2009 Jan; 11(1):33-40. PubMed ID: 18494806
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized, open-label, multicentre, parallel-controlled study comparing the efficacy and safety of biphasic insulin aspart 30 plus metformin with biphasic insulin aspart 30 monotherapy for type 2 diabetes patients inadequately controlled with oral antidiabetic drugs: The merit study.
    Guo L; Chen L; Chang B; Yang L; Liu Y; Feng B
    Diabetes Obes Metab; 2018 Dec; 20(12):2740-2747. PubMed ID: 29961975
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy, safety and acceptability of biphasic insulin aspart 30 in Indian patients with type 2 diabetes: results from the PRESENT study.
    Sharma SK; Joshi SR; Kumar A; Unnikrishnan AG; Hoskote SS; Moharana AK; Chakkarwar PN; Vaz JA;
    J Assoc Physicians India; 2008 Nov; 56():859-63. PubMed ID: 19263683
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Initiating insulin therapy with, or switching existing insulin therapy to, biphasic insulin aspart 30/70 (NovoMix 30) in routine care: safety and effectiveness in patients with type 2 diabetes in the IMPROVE observational study.
    Valensi P; Benroubi M; Borzi V; Gumprecht J; Kawamori R; Shaban J; Shah S; Shestakova M; Wenying Y;
    Int J Clin Pract; 2009 Mar; 63(3):522-31. PubMed ID: 19187170
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Insulin therapy in type 2 diabetes patients failing oral agents: cost-effectiveness of biphasic insulin aspart 70/30 vs. insulin glargine in the US.
    Ray JA; Valentine WJ; Roze S; Nicklasson L; Cobden D; Raskin P; Garber A; Palmer AJ
    Diabetes Obes Metab; 2007 Jan; 9(1):103-13. PubMed ID: 17199725
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Switching from biphasic human insulin 30 to biphasic insulin aspart 30 in type 2 diabetes is associated with improved glycaemic control and a positive safety profile: results from the A₁chieve study.
    El Naggar NK; Soewondo P; Khamseh ME; Chen JW; Haddad J
    Diabetes Res Clin Pract; 2012 Dec; 98(3):408-13. PubMed ID: 23217267
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.